



CORE BRIEF TO MANAGEMENT GROUP MEMBERS

MEETING HELD ON 25 MARCH 2021

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

1. Welcome and Introductions

The Chair welcomed members to the meeting noting that, due to the COVID-19 pandemic, the meeting was being held via MS Teams. It was noted that a quorum had been achieved.

Written questions from members and answers had been published in advance of the meeting and had been embedded within the meeting papers.

2. Action Log

Members noted the action log and received an update on:

- **MG145** - Paediatric Endocrinology: Review of activity levels – carried forward to July 2021.
- **MG210** - Paediatric Ketogenic Diet – Change in Service Model: Review of activity levels – carried forward to July 2021.

3. Managing Director's Report

Members received a paper providing updates on (1) the PET-CT Programme Business Case; (2) the revised WHSSC Risk Management Strategy; (3) UHW2; (4) de-escalation of the SBUHB TAVI service; and (5) de-escalation of the Paediatric Intensive Care services at the Children's Hospital for Wales, which was noted.

4. PET New Indications for 2021-22

Members received a paper that sought approval for the release of funding in order to implement the new PET indications included within the 2021-22 ICP.

Members (1) approved the release of funding for implementation of the 2021-22 ICP scheme for new PET indications; (2) noted the scheme is within the funding provision approved in the 2021-22 ICP; (3) noted the revised PET policy has been developed with clinical advice from the All Wales PET Advisory Group and that routine commissioning of the new policy will commence following a period of stakeholder consultation during April 2021.

5. Aortic Stenosis Clinical Pathway Development and Implementation Plan

Members received a paper that sought support for the implementation of the Aortic Stenosis Clinical Pathway Development and Implementation Plan.

It was confirmed that the recently published NICE draft clinical guidelines on heart valve disease presenting in adults and the English referral to treatment 62-day target would be taken into consideration.

Members (1) noted the information presented within the report; and (2) supported the implementation of the Aortic Stenosis Clinical Pathway Development and Implementation Plan.

6. Tuberous Sclerosis Complex Specialist Clinic: Implementation of 2021-22 ICP scheme

Members received a paper that sought approval for the release of funding to enable the implementation of the 2021-22 ICP scheme for the Tuberous Sclerosis Complex Specialist Clinic.

Members (1) approved the release of funding for the 2021-22 ICP scheme for the Tuberous Sclerosis Complex Specialist Clinic; (2) noted that the requested funding is within the provision made for Tuberous Sclerosis within the 2021-22 ICP; and (3) noted the assessment that the business case provides value for money.

7. Proposal for Syndrome Without a Name (SWAN) service

Members received a paper that informed them that the WHSS team is supporting a Rare Diseases Implementation Group (RDIG) proposal to establish a SWAN service as a 3 year pilot, backed by Welsh Government funding. The main aim of the SWAN service is to reduce the burden of the “diagnostic odyssey” experienced by patients, which is a key action identified by the RDIG.

Members noted the WHSS team support for a RDIG proposal for a pilot children’s SWAN service.

8. Traumatic Stress Wales (TSW) – Hub Staffing

Members received a paper that informed them that, following confirmation of recurrent funding from Welsh Government, the TSW hub posts (filled and unfilled) are to be made permanent. This is a Welsh Government funded initiative.

Members noted the information presented within the report.

9. CIAG process for 2021-22

Members received a paper that outlined a proposed CIAG process for 2021-22.

Members (1) considered and discussed the process and associated timeline; and (2) supported the process and associated timeline.

10. Proposals for Utilisation of Underspend

Members received a paper that reported the WHSSC Chair's Actions taken to approve proposals for the utilisation of forecast underspend, based on the Joint Committee's decision taken on 15 December 2020.

Members noted the list of proposals supported by WHSSC Corporate Directors Group Board and approved by WHSSC Chair's Action in line with the decision of Joint Committee taken on 15 December 2020.

11. Activity Report for Month 10 2020-21 COVID-19 Period

Members received a paper that highlighted the scale of the decrease in activity levels during the peak COVID-19 period, and whether there are any signs of recovery in specialised services activity. These activity decreases are shown in the context of the potential risk re patient harms and of the loss of value from nationally agreed financial block contract arrangements.

Members noted the information presented within the report.

12. 2020-21 Month 11 Finance Report

Members received a paper the purpose of which was to provide the current financial position of WHSSC together with the outturn forecast for the financial year. The financial position at month 11 is a year to date underspend of £17.5m and a forecast year end under spend of £14.2m.

This under spend under spend relates mainly to months 1-11 underspend on the pass through elements of welsh provider SLA's, NHS England anticipated underperformance against agreed block contracts where provider activity is forecast at > 20% below agreed baseline and Q1-Q4 2020-21 development slippage.

